oncaspar pegaspargase 3750 units/5ml injection solution vial
servier laboratories australia pty ltd - pegaspargase -
asparaginase 10000 u medac
medac gesellschaft fur klinische spezialpräparate mbh theaterstr. 6 22880 wedel, germany - l, asparaginase - powder for solution for injection - l-asparaginase 10000 iu - antineoplastic agents
oncaspar powder for solution for injectioninfusion 750 uml
servier (s) pte ltd - pegaspargase - injection, powder, lyophilized, for solution - pegaspargase 750 u/ml
erwinaze- asparaginase injection, powder, lyophilized, for solution
jazz pharmaceuticals, inc. - asparaginase erwinia chrysanthemi (unii: d733et3f9o) (asparaginase - unii:g4fq3cky5r) - asparaginase 10000 [iu] in 1 ml - erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (all) who have developed hypersensitivity to e. coli -derived asparaginase. erwinaze is contraindicated in patients with a history of: risk summary based on findings from animal reproduction studies, erwinaze can cause fetal harm when administered to a pregnant woman. in animal reproduction studies, intramuscular administration of asparaginase erwinia chrysanthemi to pregnant rats and rabbits during organogenesis at doses approximately 0.005-0.5 times the maximum recommended human dose resulted in structural abnormalities and embryo-fetal mortality (see data). there are no available data on erwinaze use in pregnant women to evaluate the drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. advise pregnant women of the potential risk to the fetus. the estimated background risk of major birth defects and miscarriage for the ind
dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate tablets,cii- dextroamphetami
alvogen inc. - amphetamine aspartate monohydrate (unii: o1zpv620o4) (amphetamine - unii:ck833kgx7e), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e), dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi) - amphetamine aspartate monohydrate 1.25 mg - dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets are indicated for the treatment of attention deficit hyperactivity disorder (adhd) and narcolepsy. attention deficit hyperactivity disorder (adhd) a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental eff
oncaspar liquid
aventis pharma inc - pegaspargase - liquid - 750unit - pegaspargase 750unit - antineoplastic agents
asparagus officinalis gran and glob 5ch-30ch tablet
dolisos laboratoires s.a. - asparagus officinalis - tablet - 1dh - asparagus officinalis 1dh - homeopathic products
asparagus officinalis liquid (s#129)
total health centre - asparagus officinalis - liquid - 2x - asparagus officinalis 2x - homeopathic products
asparaginase pfi 10,000iu injection
asparaginase - injection - 10,000 iu - asparaginase
asparaginase medac
medac gmbh - l-asparaginase - powder lyophilized for solution for injection - 10000u